anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PCT No. PCT/FR97/01515 Sec. 371 Date Apr. 26, 1999 Sec. 102(e) Date Apr. 26, 1999 PCT Filed Aug. 22, 1997 PCT Pub. No. WO98/08515 PCT Pub. Date Mar. 5, 1998Pharmaceutical tablet which consists of: a) a first layer having the property of swelling considerably and quickly on contact with aqueous biological fluids, the first layer being produced by compression of a mixture or of a granulate comprising hydrophilic polymers, and b) a second layer adjacent to the first layer being formulated with hydrophilic polymers and with other auxiliary substances in order to give the preparation suitable properties of compressibility and in order to allow the release of alfuzosin hydrochloride within a predetermined time period.
PROBLEM TO BE SOLVED: To obtain a depressant which exerts excellent suppressive effect on nasal cavity resistant increase, sneezing or pituita secretion by including a nitrogen monoxide (NO) production suppressive substance. SOLUTION: This depressant against nasal cavity resistant increase or the like is obtained by including a NO production suppressive substance or preferably a vascular permeability and vasodilation suppressive substance. As the above substance, e.g. N-nitro-L-arginine (methyl ester), methyl guanidine, dimethyl guanidine, amino guanidine, monomethyl arginine, nitro arginine, S- ethyl isothiourea, 2-iminopiperidine or the like is illustrated. The content of the above substance is usually about 0.1-100 wt.% based on the whole weight of a pharmaceutical preparation. This depressant may be administrated by both oral and parenteral routes. For example, it is administrated usually at a once dose of about 0.1-20 mg/kg body weight when orally administrated to an adult patient (60 kg) for the purpose of treating nasal cavity resistant increase.
PROBLEM TO BE SOLVED: To obtain a mousse form cosmetic composition capable of being uniformly distributed on application and capable of giving excellent styling characteristics, adhesivity and smooth touch to keratin substances such as skin and hair. SOLUTION: This mousse form cosmetic composition contains 0.01-5 wt.% of an associated polyurethane such as a polymer of the formula: X-Bp -Eq (B-E)n - Br -Et -X [(n) is 1-10; (p), (q), (r), (t) are each 0, 1, etc.; X is a hydrophobic group; B is a divalent hydrophobic group; E is a divalent nonionic polyether) and 0.1-20 wt.% of an anionic polymer such as a polymer of the formula (A is methylene; R1 is H, phenyl, etc.; R2 is H, a lower alkyl, etc.; R3 is H, benzyl, etc.), in a cosmetic medium. At least one of the two polymers is a foamable polymer, and forms a compressed mousse form as an aerosol in the presence of an aerosol propellant. The addition of the associated polyurethane remarkably improves the rigidity, expansibility and stability of the aerosol mousse.
Pulmonary arterial hypertension is characterized by decompensated increase of pulmonary artery pressure owing to continuous progression of pulmonary vascular resistance and can ultimately cause right heart failure even death. At present, the treatment of pulmonary arterial hypertension is mainly the application of specific drug therapy. Specific drug therapy involves the three major pathways of endothelin, nitric oxide and prostacyclin. The main mechanisms of vasodilation and anti-proliferation are used to treat pulmonary arterial hypertension. However, the price of specific drug therapy is too expensive, which puts huge financial pressure on patients. Evidence shows that inflammation exists in the early stages of pulmonary arterial hypertension and anti-inflammatory treatment is effective in animal experiments. Under placebo control, the investigators intend to evaluate the effectiveness and safety of anti-inflammatory therapy and/or targeted drug therapy for early treatment of patients with pulmonary arterial hypertension.
REBYOTA (fecal microbiota, live – jslm) is an opaque fecal microbiota suspension for rectal administration. REBYOTA is manufactured from human fecal matter sourced from qualified donors. The human fecal matter is tested for a panel of transmissible pathogens. Donors do not have dietary restrictions with respect to potential food allergens. The fecal microbiota suspension is the filtrate generated by processing the fecal matter in a pre-defined ratio with a solution of polyethylene glycol (PEG) 3350 and saline. Each 150mL dose of REBYOTA contains between 1×108 and 5×1010 colony forming units (CFU) per mL of fecal microbes including >1×105 CFU/mL of Bacteroides, and contains not greater than 5.97 grams of PEG3350 in saline.
Simultaneously with MIME treatment, patients will undergo transcranial direct current stimulation (tDCS). Stimulation with tDCS will begin 5 minutes after the start of resting phase 1, and the electrodes will be placed as follows: the 5×4 anode (about 20 cm2) will be placed on the left dorsolateral prefrontal area; the reference electrode, 6x5 (about 30 cm2), will instead be placed on the upper arm, specifically at the level of the right deltoid muscle, contralateral to the active electrode. Current will be applied at an intensity of 2 mA, for 20 minutes a day for 2 weeks, five days a week, for a total of 10 sessions. The current density will be kept below the safe limits reported in the literature.
Metastatic recurrence is still a major challenge in breast cancer treatment. Patients with triple negative breast cancer (TNBC) develop early recurrence and relapse more frequently. Due to the lack of specific therapeutic targets, new targeted therapies for TNBC are urgently needed. Phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway is one of the active pathways involved in chemoresistance and survival of TNBC, being considered as a potential target for TNBC treatment. Our present study identified ticagrelor, an anti-platelet drug, as a pan-PI3K inhibitor with potent inhibitory activity against four isoforms of class I PI3K. At doses normally used in clinic, ticagrelor showed weak cytotoxicity against a panel of breast cancer cells, but significantly inhibited the migration, invasion and the actin cytoskeleton organization of human TNBC MDA-MB-231 and SUM-159PT cells. Mechanistically, ticagrelor effectively inhibited PI3K downstream mTOR complex 1 (mTORC1) and mTORC2 signaling by targeting PI3K and decreased the protein expression of epithelial-mesenchymal transition (EMT) markers. In vivo, ticagrelor significantly suppressed tumor cells lung metastasis in 4T1 tumor bearing BALB/c mice model and experimental lung metastasis model which was established by tail vein injection of GFP-labeled MDA-MB-231 cells. The above data demonstrated that ticagrelor can inhibit the migration and invasion of TNBC both in vitro and in vivo by targeting PI3K, suggesting that ticagrelor, a pan-PI3K inhibitor, might represent a promising therapeutic agent for the treatment of metastatic TNBC.
The present invention discloses medicine for treating hyperosteogeny, which belongs to one of medicine for treating osteopathy. The present invention is characterized in that the effective components of the medicine mainly comprise safflower or red sage root or 18 to 30% of motherwort, 20 to 30% of angelica, 20 to 30% of eucommia bark, 10 to 20% of achyranthes root and 10 to 18% of scrophularia root. The medicine can effectively treat limb numbness, acid swollen pain, weakness, spasticity, crooked feet, head section pain, dizziness, nausea, vomiting, tinnitus, blurred vision, chest stuffiness, palpitation, etc. because of hyperosteogeny. Besides, diseases have no recurrence after curing. The present invention has no toxic and side effect, and has low cost because the ingredients are normal medicine and few.
<P>PROBLEM TO BE SOLVED: To provide a highly safe anti-androgenic hormone preparation or hair papilla cell proliferation enhancer having at least either one of testosterone 5α-reductase activity inhibitory effect, androgen receptor antagonism and hair papilla cell proliferation enhancing effect.  <P>SOLUTION: The anti-androgenic hormone preparation contains at least one of Myrica cerifera extract, Piper kadzura extract and Agrimonia pilosa extract. The hair papilla cell proliferation enhancer contains at least one of Myrica cerifera extract and Vaccinium spp. extract. A preparation for external use for the scalp and the hair containing the anti-androgenic hormone preparation and/or the hair papilla cell proliferation enhancer is also provided.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Although inflammation is primarily a protective response guarding the human body, it can result in a variety of chronic diseases such as allergies, auto-immune, cardiovascular diseases, and cancer. In NF-κB-mediated inflammation, many small molecules and food compounds characterized as nutraceuticals have shown positive effects associated with immunomodulatory properties. We investigated the effects of selected bioactive small molecules, commonly found in food components, vanillyl alcohol (VA) and lauric acid (LA), on different cell lines exposed to pro-inflammatory stimuli, lipopolysaccharide (LPS), and the food allergen actinidin (Act d 1). Pro-inflammatory cytokines were downregulated in response to both VA and LA, and this downregulation was caused by a decrease in the activation of the NF-κB pathway and the translocation of p65, the pathway's major component. Small nutraceutical molecules, VA and LA, showed not only inhibition of the pro-inflammatory cytokines, but also inhibition of the NF-κB activation, and reduced translocation of the p65 component. The present study may contribute to the therapeutic use of these molecules for various inflammatory diseases, which have in common an increased expression of pro-inflammatory cytokines and NF-κB-mediated inflammation.
BACKGROUND: Previous studies suggest an association between schizophrenia and stroke, but no studies have investigated stroke subtypes. We examined potential causal associations between schizophrenia and a range of atherosclerotic, embolic, and hemorrhagic stroke outcomes.
METHODS AND RESULTS: Two-sample Mendelian randomization analyses were conducted. The summary-level data (restricted to European ancestry) were obtained for schizophrenia and stroke: ischemic stroke, large-artery stroke, small-vessel stroke, cardioembolic stroke, and intracerebral hemorrhage. The associations between schizophrenia and each outcome were analyzed by an inverse variance weighting method primarily and Mendelian randomization Egger, weighted median, and weighted mode subsequently. The presence of pleiotropy was also tested by Cochran Q statistic, I2 index, and Mendelian randomization Egger intercept with scatter and funnel plots. We found associations between schizophrenia and cardioembolic stroke (odds ratio [OR], 1.070 [95% CI, 1.023-1.119]) and intracerebral hemorrhage (OR, 1.089 [95% CI, 1.005-1.180]) using inverse variance weighting. Little evidence of associations with the other stroke subtypes was found. Different Mendelian randomization methods corroborated the association with cardioembolic stroke but not intracerebral hemorrhage.
CONCLUSIONS: We have provided evidence of a potentially causal association between schizophrenia and cardioembolic stroke. Our findings suggest that cardiac evaluation should be considered for those with schizophrenia.
AIMS: The prospective GULLIVE-R study aimed to evaluate adherence to guideline-recommended secondary prevention, physicians' and patients' estimation of cardiac risk, and patients' knowledge about target values of risk factors after acute myocardial infarction (AMI).
METHODS AND RESULTS: We performed a prospective study enrolling patients 9-12 months after AMI. Guideline-recommended secondary prevention therapies and physicians as well as patients' estimation about their risk and patients' knowledge about target values were prospectively collected. Between July 2019 and June 2021, a total of 2509 outpatients were enrolled in 150 German centres 10 months after AMI. The mean age was 66 years, 26.4% were women, 45.3% had ST elevation myocardial infarction, 54.7% had non-ST elevation myocardial infarction, and 93.6% had revascularization (84.0% percutaneous coronary intervention, 7.4% coronary artery bypass graft, 1.8% both). Guideline-recommended secondary drug therapies were prescribed in over 80% of patients, while only about 50% received all five recommended drugs (aspirin, P2Y12 inhibitors, statins, beta-blockers, renin-angiotensin-aldosterone system inhibitors), and regular exercise was performed by only one-third. About 90% of patients felt well informed about secondary prevention, but the correct target value for blood pressure was known in only 37.9% and for LDL-cholesterol in only 8.2%. Both physicians and patients underestimated the objective risk of future AMIs as determined by the thormbolysis in myocardial infarction (TIMI) risk score for secondary prevention.
CONCLUSION: There is still room for improvement in patient education and implementation of guideline-recommended non-pharmacological and pharmacological secondary prevention therapies in patients in the chronic phase after AMI.
Combinations of antiretroviral nucleoside reverse transcriptase inhibitors, and methods for their use in treating retroviral infections, are provided. In one embodiment, the combinations include non-thymidine nucleoside antiretroviral agents, such as tenofovir-DF, abacavir, APD and DAPD, that select for the K65R mutation and relatively low doses of zidovudine (AZT) or other thymidine nucleoside antiretroviral agents. The thymidine nucleoside antiretroviral agents retard development of the K65R mutation, and at the low doses, are less likely to produce side effects. In another embodiment, the combinations include DAPD and AZT. DAPD retards the development of TAMs, and AZT retards the development of the K65R mutation. In a third embodiment, the combinations include adenine, cytosine, thymidine, and guanine nucleoside antiviral agents, in further combination with at least one additional antiviral agent that works via a different mechanism than a nucleoside analog. This combination has the potential to eliminate the presence of HIV in an infected patient.
In the prodn. of temp.-controlled (i.e., warned) aerosols for the treatment of humans or animals (esp. with atomised brine), the treatment liq. or brine is atomised by means of a gaseous propellant medium (esp. air) and an aerosol stream is formed directed into the space occupied by the patient or patients. On leaving the atomiser, the aerosol stream is enclosed by a substantially parallel stream or warmed gas (esp. air), this parallel stream being admixed into the aerosol stream before reaching the space occupied by the patient(s). Appts. comprises an aerosol feed channel between an aerosol atomiser and the attachment to the patient or the space occupied by the patient, this being surrounded by a heating mantle for heating gas which is injected into the aerosol stream at an appropriate point. Used in the application of e.g., spa waters in aerosol form for therapeutic purposes. Surrounding the stream of atomised liq. with arm gas (esp. air) counteracts the undesirable adiabatic cooling effect.
Dithiocarbamic compounds, administered about 0.5 to about 6 hours after Pt compounds, have been found to counter the toxicity of the platinum in multicellular organisms (e.g. mammals). For example, neoplastic growths in mammals can be treated with cis-diamine or cis-diammine Pt(II) complexes with greatly lessened risk of nephrotoxicity, bone marrow toxicity, or damage to the digestive system of the mammal, provided the dithiocarbamic compound is timely (and preferably parenterally) administered. Particularly effective dithiocarbamic compounds are monomeric (e.g.   <IMAGE>   where M is a pharmaceutically acceptable cation and R1 and R2 are lower aliphatic (or cycloaliphatic or heterocycloaliphatic groups) or, less preferably, dimeric, e.g.   <IMAGE>  wherein R1 and R2 are as defined previously, and R3 and R4 are defined in the same manner as R1 and R2. These dithiocarbamic compounds do not significantly reduce the desired effect of the Pt(II) compounds (particularly when the dithiocarbamic compound is intravenously administered), despite their effectiveness in reducing harmful side effects.
For patients in the conservative fluid management arm, beginning 12 hours after admission to study ICU and ending at the first of ICU discharge, death, return to home inspired oxygen, or study day 14, fluid management will be controlled by a study protocol. Patients in shock will receive fluid boluses only as specified by the protocol for oliguria and rapidly increasing vasopressor requirement. Patients not in shock will receive fluid boluses only as specified by the protocol for oliguria. Output will exceed input each day using a diuretic drip if required. Study protocol will be held only for pre-specified Safety Endpoints of persistent oliguria, decompensating shock, diuretic side effect, and intervening acute event.
Participants in this arm will receive the Move to Music (M2M) only intervention without video. The participant will be asked to exercise twice daily for 5 consecutive days.
Patients receive methylprednisolone IV over 10 minutes on days 1-4 and IV or PO with taper over days 5-30. Patients also receive horse anti-thymocyte globulin IV over 8 hours daily on days 1-4, cyclosporine PO BID on days 1-180, and pegfilgrastim or pegfilgrastim biosimilar SC on day 5 and/or filgrastim SC beginning on day 5 and continuing until absolute neutrophil count recovers. Treatment continues for up to 6 months in the absence of disease progression or unacceptable toxicity.
PURPOSE:To prevent skin stimulation with scattered fibers, which occurs in the use of inorganic fiber, etc., by applying liquid paraffin or paraffin chloride homogeneously on the inorganic fiber. CONSTITUTION:An inorganic fiber, e.g. glass fiber, ceramic fiber or rock wool is treated with a treating liquid containing liquid paraffin or paraffin chloride homogeneously dispersed or dissolved in water, an organic solvent (e.g. benzene or toluene) or their mixture. In this treatment, the treating liquid is sprayed or coated on the inorganic fiber or the inorganic fiber is immersed in the treating liquid and the treated inorganic fiber is dried. This processing enables the prevention of skin stimulation caused by the direct contact or the indirect contact with scattered fibers and the scattering of the fiber during the production or processing or in the use of the inorganic fiber. Further, the addition of synthetic resin (e.g. polyvinyl acetate) emulsion (or solution) to the treating liquid enhances the preventive effect on scattering of fibers.
The Ronald Morris Disability Questionnaire will be translated into Urdu and culturally adapted for people with low back pain. Ronald Morris Disability Questionnaire will be given to 80 people who will be chosen by using a convenient sampling method. Method of sampling based on pre-determined inclusion and exclusion criteria. To examine intra-observer reliability of the final Ronald Morris Disability Questionnaire, two observers will fill out Oswestry Disability Index and Visual Analogue Scale questionnaires on the same day to test inter-observer evaluation. After 30 minutes of the initial treatment, the second application will be applied. The first observer will do the third assessment after seven days. Statistical Package of Social Sciences Version 24 will be used to enter and analyse data. The alpha value of Cronbach's alpha will be examined.
507,376. Antipoliomyelitis serum. WESTERN RESERVE UNIVERSITY. May 26, 1938,' No. 15795. Convention date, May 29, 1937. [Class 81 (i)] A serum effective against the virus of poliomyelitis is obtained by immunizing an animal by successive injections of poliomyelitis virus fortified with products of metabolism of intestinal bacteria and obtaining a serum from the blood of the animal. Material for fortifying the virus may for example comprise the endotoxins from strains of typhoid, paratyphoid and coli bacteria, together with the exotoxins from the growth of these strains in glucose broth. A solution of the virus in normal saline with which the fortifying material is to be admixed may be obtained by adsorbing the virus on aluminium hydroxide gel and eluting the adsorbed virus.
The pilot study was conducted in a primary health centre (population \~33000) in Faridabad district of the state of Haryana in India. Formative research identified perceptions of caregivers regarding childhood diarrhea, causation and management, care seeking sources and caregivers expectations from healthcare providers. Caregivers in households with children under 5 years old were interviewed in a cross sectional survey to ascertain family characteristics, ORS prescription and use rates, drug prescription rates by healthcare providers and other variables of interest.

In partnership with the local government, channels for distribution of zinc and ORS packets were defined. The channels included physicians (at PHC and private practitioners), auxiliary nurse midwives (ANMs) and Anganwadi workers (AWWs)of the Integrated Child Development Services (ICDS) scheme. Recommendations were developed and translated into local vernacular. A poster, which incorporated the recommendations and pictures of zinc strip and ORS packets, was designed. These posters were put up at different places in the study area. All channels were trained and provided with the supplies of zinc strips and ORS packets except the private practitioners who received only zinc strips and advised caregivers to take ORS packets from government channels. Effectiveness of this pilot program was assessed through 2 cross sectional surveys, 3 and 6 months post training.

The cross sectional surveys revealed that the prescription of syrups, tablets, powders and injections during diarrhea and cost of treatment decreased significantly. Prescription and use of ORS increased markedly. Zinc tablets were prescribed and used in about half the episodes 6 months after start of intervention. It was feasible to train various government and community channels to promote zinc as treatment of acute diarrhea through the primary health care system.
Our objective was to evaluate the clinical effectiveness of the SYNERGY stent (Boston Scientific Corporation, Marlborough, Massachusetts) in patients with ST-elevation myocardial infarction (STEMI). The only drug-eluting stent approved for treatment of STEMI by the Food and Drug Administration is the Taxus stent (Boston Scientific) which is no longer commercially available, so further data are needed. The CLEAR (Colchicine and spironolactone in patients with myocardial infarction) SYNERGY stent registry was embedded into a larger randomized trial of patients with STEMI (n = 7,000), comparing colchicine versus placebo and spironolactone versus placebo. The primary outcome for the SYNERGY stent registry is major adverse cardiac events (MACE) as defined by cardiovascular death, recurrent MI, or unplanned ischemia-driven target vessel revascularization within 12 months. We estimated a MACE rate of 6.3% at 12 months after primary percutaneous coronary intervention for STEMI based on the Thrombectomy vs percutaneous coronary intervention alone in STEMI (TOTAL) trial. Success was defined as upper bound of confidence interval (CI) to be less than the performance goal of 9.45%. Overall, 733 patients were enrolled from 8 countries with a mean age 60 years, 19.4% diabetes mellitus, 41.3% anterior MI, and median door-to-balloon time of 72 minutes. The MACE rate was 4.8% (95% CI 3.2 to 6.3%) at 12 months which met the success criteria against performance goal of 9.45%. The rates of cardiovascular death, recurrent MI, or target vessel revascularization were 2.7%, 1.9%, 1.0%, respectively. The rates of acute definite stent thrombosis were 0.3%, subacute 0.4%, late 0.4%, and cumulative stent thrombosis of 1.1% at 12 months. In conclusion, the SYNERGY stent in STEMI performed well and was successful compared with the performance goal based on previous trials.